Dr. Brody on the Expanding Role of Venetoclax in MCL

Video

In Partnership With:

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Joshua Brody, MD, director of the Lymphoma program at Icahn School of Medicine, Mount Sinai Hospital, discusses the expanding role of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Venetoclax, a BCL-2 inhibitor, as a single agent or in combination with obinutuzumab (Gazyva) currently has FDA approvals in chronic lymphocytic leukemia and acute myeloid leukemia, says Brody. In MCL, venetoclax appears to be a promising emerging agent for patients with BTK inhibitor–refractory and –naïve disease.

Data with venetoclax have shown high overall and complete response rates with durable remissions in patients with MCL, Brody says. Additionally, the toxicity profile of venetoclax in MCL appears similar to what has been observed in CLL, explains Brody. Regarding safety, venetoclax poses an early risk of tumor lysis syndrome; however, the risk appears to be manageable with standard dose titration.


Overall, it is difficult to predict which B-cell malignancies venetoclax will have activity in, says Brody. However, as BCL-2 is widely expressed in MCL, there is rationale to evaluate the agent in this space, concludes Brody.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,